FindTrial
Sign In

A multicenter clinical study using bidirectional cohort to evaluate application of serum biomarker in predicting prognosis of diffuse large B-cell lymphoma

A multicenter clinical study using bidirectional cohort to evaluate application of serum biomarker in predicting prognosis of diffuse large B-cell lymphoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800016867
Enrollment
Unknown
Registered
2018-06-30
Start date
2018-07-01
Completion date
Unknown
Last updated
2018-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse large B-cell lymphoma

Interventions

Gold Standard:Clinical outcome
Index test:serum&#32
biomarker&#32
Ion-T&#32
in&#32
DLBCL&#32
patients

Sponsors

Renji Hospital, Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients with newly diagnosed diffuse large B-cell lymphoma aged = 18 years old; 2) Expected survival period =12 weeks; 3) Vein sampling pathway available for serum collection 4) Ccr =30ml/min; 5) ALT and AST =3×ULN.

Exclusion criteria

Exclusion criteria: 1) Pathology diagnosis does not meet diffuse large B-cell lymphoma reviewed by pathologist; 2) Intravenous drug use within 48 hours before collection of serum; 3) Pregnant or lactating women; 4) Cannot tolerate or reject anti-tumor therapy

Design outcomes

Primary

MeasureTime frame
3-year progression free survival;—

Secondary

MeasureTime frame
treatment response;relapse;follow-up costs;—

Countries

China

Contacts

Public ContactTing WANG

Renji Hospital, Shanghai Jiaotong University School of Medicine

tingwang2000@126.com+86 15821216939

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026